Sanmarti R, et al. - Researchers evaluated whether an increase in the dose interval of subcutaneous tocilizumab in patients with rheumatoid arthritis (RA) who were in clinical remission, was effective and safe. They administered 162 mg of subcutaneous tocilizumab once weekly as monotherapy (TCZ-SCqw) or the csDMARD combination for 24 weeks to patients with RA, active disease and an inadequate response to csDMARDS or one biological agent in this single-arm phase study. Findings revealed a lower probability of maintaining remission after 24 weeks and no better tolerability in correlation with increasing the dose interval of subcutaneous TCZ. However, a half-dose of subcutaneous TCZ led to sustained remission in most patients, and therefore further investigation of this strategy is recommended.